Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2022 / N 1

Терапия сосудистых коморбидных пациентов с хронической ишемией мозга в эпоху коронавирусной пандемии
И.П. Амелина, Э.Ю. Соловьева

References

1. Ministry of Health of the Russian Federation. Russian Medical Society on Arterial Hypertension. Clinical recommendations. Arterial hypertension in adults. ICD 10: I10/I11/I12/I13/I15. Year of approval (frequency of revision): 2016 (revision every 3 years). ID: KR62. Available from: http://cr.rosminzdrav.ru /#!/schema/687 Accessed 2022 Mar 14. (In Russian).
2. Savva GM, Stephan BC; Alzheimer’s Society Vascular Dementia Systematic Review Group. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010 Jan;41(1):e41-6.
3. Oganov RG. Fight against cardiovascular diseases – contribution of the state, civil society, and man. In: Proceedings of the 9th All-Russian forum «Health of the nation is the basis of Russia’s prosperity». Moscow, 09-11 Apr 2015. Moscow, 2015. (In Russian).
4. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal F, Wardlaw JM. Neuropsychiatric symptoms associate with cerebral small vessel disease: systematic review and meta-analysis. The Lancet. Psychiatry 2021 Mar;8(3):225-36.
5. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. The Lancet. Neurology 2019 Jul;18(7):684-96.
6. Kulesh AA, Yemelin AYu, Bogolepova AN, Doronina OB, Zakharov VV, Kolokolov OV, Kotov SV, Korsunskaya LL, Kutlubayev MA, Laskov VB, Levin OS, Parfenov VA. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Neurology, Neuropsychiatry, Psychosomatics 2021;13(1):4-12 (In Russian).
7. Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, Dichgans M. Vascular cognitive impairment and dementia: JACC Scientific Expert Panel. Journal of the American College of Cardiology 2019 Jul;73(25):3326-44.
8. Heiss WD, Rosenberg GA, Thiel A, Berlot R, de Reuck J. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC Medicine 2016 Nov;14(1):174.
9. Dichgans M, Leys D. Vascular cognitive impairment. Circulation Research 2017 Feb;120(3):573-91.
10. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012 Dec;380(9859):2095-128.
11. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. The Lancet. Neurology 2007 Jul;6(7):611-9.
12. Solovyeva EY, Amelina IP. Cerebral small vessel disease’s impact on the development of chronic cerebral ischemia: paradigms of treatment. Medical Council 2020;2:16-24 (In Russian).
13. Gulevskaya TS, Morgunov VA. Pathological anatomy of cerebral circulation disorders in atherosclerosis and arterial hypertension. Moscow: Meditsina; 2009. 296 p. (In Russian).
14. Fedin AI, Starykh EP, Parfenov AS, Mironova OP, Abdrakhmanova EK, Starykh EV. Pharmacological of endothelial dysfunction in patients with atherosclerotic brain ischemia. SS Korsakov Journal of Neurology and Psychiatry 2013;113(10):45-8 (In Russian).
15. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey CJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. The Lancet 2010 Jul;376(9735):112-23.
16. Nishimura N, Rosidi NL, Iadecola C, Schaffer CB. Limitations of collateral flow after occlusion of a single cortical penetrating arteriole. Journal of Cerebral Blood Flow & Metabolism 2010 Dec;30(12):1914-27.
17. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. The Lancet. Neurology 2010 Jul;9(7):689-701.
18. Kampoli AM, Tousoulis D, Briasoulis A, Latsios G, Papageorgiou N, Stefanadis C. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Current Pharmaceutical Design 2011 Dec;17(37):4147-58.
19. Buvaltsev VI. Vasodilating function of endothelium and possible ways of its correction in patients with arterial hypertension [Dissertation for the Degree of Doctor of Medical Sciences]. Moscow, 2003. 222 p. (In Russian).
20. Sabayan B, Westendorp RG, van der Grond J, Stott DJ, Sattar N, van Osch MJP, van Buchem MA, de Craen AJM. Markers of endothelial dysfunction and cerebral blood flow in older adults. Neurobiology of Aging 2014;35(2):373-7.
21. Bulayeva NI, Golukhova EZ. Endothelial dysfunction and oxidative stress: role in cardiovascular pathology. Creative Cardiology 2013;1:14-22 (In Russian).
22. Vlasov TD, Petrishchev NN. Physiology and pathophysiology of endothelium. In: Endothelial dysfunction. Causes, mechanisms, pharmacological correction: collection of articles. Petrishchev NN, editor. St. Petersburg: St. Petersburg SMU; 2003: 4-38 (In Russian).
23. Domashenko MA. Endothelial dysfunction in acute period of ischemic stroke [Dissertation for the Degree of Candidate of Medical Sciences]. Moscow, 2006. 130 p. (In Russian).
24. Suslina ZA, Tanashyan MM, Ionova VG. Ischemic stroke: blood, vessel wall, antithrombotic therapy. Moscow: Meditsinskaya Kniga; 2005. 248 p. (In Russian).
25. Nakayama M, Yamamuro M, Takashio S, Uemura T, Nakayama N, Hirakawa K, Oda S, Utsunomiya D, Kaikita K, Hokimoto S, Yamashita Y, Morita Y, Kimura K, Tamura K, Tsujita K. Late gadolinium enhancement on cardiac magnetic resonance imaging is associated with coronary endothelial dysfunction in patients with dilated cardiomyopathy. Heart and Vessels 2017 Apr;33(4):393-402.
26. Bryushkov AI, Yershov PV, Sergeyeva NA, Bogachev VYu. On possible role of endothelial dysfunction in development of acute venous thrombosis. Angiology and Vascular Surgery 2016;22(1):91-6 (In Russian).
27. Castro-Ferreira R, Cardoso R, Leite-Moreira A, Mansilha A. The role of endothelial dysfunction and inflammation in chronic venous disease. Annals of Vascular Surgery 2018 Jan;46:380-93.
28. Frump A, Prewitt A, de Caestecker MP. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series). Pulmonary Circulation 2018 Apr-Jun;8(2):2045894018765840.
29. Peng HY, Li HP, Li MQ. High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus. Microvascular Research 2018 Jul;118:90-100.
30. Suchkov IA, Pshennikov AS, Gerasimov AA, Agapov AB, Kamayev AA. Prophylaxis of restenosis in reconstructive surgery of main arteries. Science of the Young (Eruditio Juvenium) 2013;2:12-9 (In Russian).
31. Kostyuchenko GI, Barkagan ZS. Hyperhomocysteinemia and coronary heart disease: problem of the elderly. Clinical Gerontology 2003;5:9-12 (In Russian).
32. Ter Telgte A, van Leijsen EMC, Wiegertjes K, Klijn CJM, Tuladhar AM, de Leeuw FE. Cerebral small vessel disease: from a focal to a global perspective. Nature Reviews. Neurology 2018 Jul;14(7):387-98.
33. Kraft P, Schuhmann MK, Garz C, Jandke S, Urlaub D, Mencl S, Zernecke A, Heinze HJ, Carare RO, Kleinschnitz C, Schreiber S. Hypercholesterolemia induced cerebral small vessel disease. PLoS One 2017 Aug;12(8):e0182822.
34. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders 2010;11(1):61-74.
35. Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. European Heart Journal 2014 Apr;35(14):888-94.
36. Nikonov VV, Nudga AN, Kovaleva EA, Sidorenko OA. Actovegin in treatment of patients with unstable angina. Emergency Medicine 2008;1(14). (In Russian).
37. Ushkalova EA. Antioxidant and antihypoxic properties of actovegin in cardiac patients. Difficult Patient 2005;3(3):22-6 (In Russian).
38. Orlova AS. Somatic disorders and free radical processes in cerebrovascular disease. Fundamental Research 2012;8-1:220-4 (In Russian).
39. Li W, Moore M, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 Nov;426(6965):450-4.
40. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertension Research 2020 Jul;43(7):648-54.
41. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiological Reviews 2020 Jul;100(3):1065-75.
42. Alnefeesi Y, Siegel A, Lui LMW, Teopiz KM, Ho RCM, Lee Y, Nasri F, Gill H, Lin K, Cao B, Rosenblat JD, McIntyre RS. Impact of SARS-CoV-2 infection on cognitive function: a systematic review. Frontiers in Psychiatry 2021 Feb;11:621773.
43. Putilina MV. Role of endothelial dysfunction in cerebrovascular diseases. Vrach 2012;7:24-8 (In Russian).
44. Putilina MV, Teplova NV, Gerasimova OS. Differentiated approach to treatment of cognitive disorders associated with SARS-CoV-2 (COVID-19) taking into account comorbidity factor. Medical Alphabet 2021;22:18-24 (In Russian).
45. Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential treatment strategies. SS Korsakov Journal of Neurology and Psychiatry 2020;120(8-2):58-64 (In Russian).
46. Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clinical and Applied Thrombosis/Hemostasis 2020 Jan-Dec;26:1076029620943293.
47. Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Neurology, Neuropsychiatry, Psychosomatics 2019;11(3 Suppl):61-7 (In Russian).
48. Van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nature Review. Disease Primers 2018 Feb;4:18003.
49. Philip BM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. International Journal of Stroke 2015 Jun;10(4):469-78.
50. Stupin VA, Rumyantseva SA, Silina EV. Vascular complications of diabetes mellitus. Educational and methodical manual. Moscow: RSMU; 2009 (In Russian).
51. Wiernsperger NF. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular disease. Journal of Cardiovascular Pharmacology 1994;23(Suppl 3):37-43.
52. Wang W, Wang LN, Zhang XH, Ma L, Li DJ. [A nimodipine interventional study of patients with mild cognitive impairment]. Zhonghua Nei Ke Za Zhi 2006 Apr;45(4):274-6.
53. Marconi A, Darquenne S, Boulmerka A, Mosnier M, D’Alessio P. Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. Free Radical Biology & Medicine 2003 Mar;34(5):616-25.
54. Belova AN, Shakurova DN, Gayazova EV. Possibilities of using naftidrofuryl in the therapy of cerebrovascular diseases: literature review and the authors’ observations. Neurology, Neuropsychiatry, Psychosomatics 2015;7(4):110-5.
55. Zolotovskaya IA, Davydkin IL. Possibilities of pharmacological correction of structural and functional alterations of microcirculation in terms of endothelial dysfunction in comorbid patients suffered stroke event. Klinitsist 2016;10(2):32-42 (In Russian).
56. Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, Fimiani F, Pariggiano I, Diana V, Carbone A, Cesaro A, Concilio C, Limongelli G, Russo M, Calabrò P. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators of Inflammation 2017;2017:5620314.
57. Dadasheva MN, Zolotovskaya IA, Gorenkov RV, Dadasheva KN, Lebedeva DI. Evaluation of the efficacy and tolerability of naftidrofuryl in the therapy of chronic cerebral ischemia. Neurology, Neuropsychiatry, Psychosomatics 2021;13(1):38-43 (In Russian).
58. Fedin AI. Neurological complications of COVID-19. Neuronews 2021;11(85):13 (In Russian).
59. Kovalchuk V, Tokareva E. Medication as possibility of functional rehabilitation’s improvement in stroke patients. Vrach 2015;9:52-4 (In Russian).
60. Capon A, Lehert P, Opsomer L. Naftidrofuryl in the treatment of subacute stroke. Journal of Cardiovascular Pharmacology 1990;16(Suppl 3):S62-6.
61. Parfenov VA, Lokshina AB, Gishina DA, Starchina YuA, Kosivtsova OV. Naphtidrofuril use in moderate vascular cognitive disorders. Medical Council 2017;S:22-6 (In Russian).
62. Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. The Cochrane Database of Systematic Reviews 2011 Dec 7;(12):CD002955.
63. Grossman WM, Standl A, May U, van Laak HH, Hirche H. Naftidrofuryl in the treatment of mild senile dementia. A double-blind study. Pharmacopsychiatry 1990 Nov;23(6):265-73.
64. Saldmann F, Funel A, Jacquet P. Efficacy of naftidrofuryl in patients with moderate senile dementia. Current Medical Research and Opinion 1991;12(6):379-89.
65. Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double blind trial. Clinical Therapeutics 2000 Jul;22(7):834-44.
66. Möller H, Hartmann A, Kessler C, Rainer M, Brown T, Gamand S, Lehert P. Naftidrofuryl in the treatment of vascular dementia. European Archives of Psychiatry and Clinical Neuroscience 2001 Dec;251(6):247-54.
67. Boeijinga PH, Nedelec JF, Demazières A, Souan ML, Gamand S, Gilles C, Parot P, Staner L, Luthringer R, Macher JP. Characterization of the CNS effects of naftidrofuryl (Praxilène) by quantitative EEG and functional MRI: a study in healthy elderly subjects. Neuropsychobiology 2003;48(3):160-8.
68. Költringer P, Langsteger W, Reisecker F, Eber O. Effect of naftidrofuryl on viscoelasticity, thrombocyte aggregation and erythrocyte fluidity of blood. Vasa 1992;21(4):411-4.
69. Kapustin RV. Influent of enelbin on neurohumoral homeostasis in dyscirculatory angioencephalopathy caused by hypertension. Bulletin of VN Karazin Kharkiv National University 2003;6(597):49-52 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]